Market Signal Briefing

207 billion SHIB tokens exit exchanges in 24-Hour period, largest outflow in months.

Summary

207 billion SHIB tokens exited exchanges in 24 hours, marking the largest withdrawal in months.
Despite major outflows, SHIB’s price remained stable due to weak market momentum and technical resistance.
Investors show neutral stance, holding tokens as Shiba Inu awaits new project announcements.

Shiba Inu (SHIB) experienced a major withdrawal event when 207 billion SHIB tokens exited cryptocurrency exchanges throughout a single day according to CryptoQuant data. The recent withdrawal stands as one of the biggest single-day withdrawals since the last few months.

The CryptoQuant data shows that 121 billion SHIB tokens left exchanges during November 15 before continuing their exit pattern into November 16.

The exchange supply reduction failed to influence SHIB price movements because of existing technical obstacles. The token operated at a support area when analysts conducted their assessment. The Relative Strength Index showed 39 while all major moving averages maintained positions above current market value according to technical analysis.

The Relative Strength Index showed 39 which indicates weak market momentum. The trading activity stayed at a constant level because investors chose to keep their positions instead of selling their assets according to market statistics.

Technical analysts predict SHIB needs to break past its current support levels to test the first resistance area where moving averages intersect. The current token price remains below both resistance levels which have not faced testing since the start of the token outflow.

The exchange data shows no connection between market price movements and token withdrawal activities. The accelerated exchange token withdrawals create a situation where sellers face reduced available supply. Market participants who remove their tokens from exchanges indicate they want to keep their positions instead of selling their assets.

The current market behavior differs from distribution patterns because tokens enter exchanges before investors start selling. The historical data indicates that prolonged exchange withdrawals have led to market trend changes although investors cannot predict when these events will occur.

The current market value of Shiba Inu stands at 90% below its peak market value. The cryptocurrency market experienced significant price fluctuations during November according to market reports.

The Shiba Inu development team has announced upcoming projects but they have not revealed any details about these initiatives. Market observers note that trading activity indicates investors have taken a neutral stance instead of buying or selling their tokens.

The derivatives arm of Singapore Exchange (SGX) said on Monday that it would launch bitcoin and ether cryptocurrency perpetual futures trading on its platform.

Most institutional Bitcoin investors are unaware or unconcerned about the Core vs Knots debate.

Nick Szabo, a prominent Bitcoin pioneer and early developer of smart contracts, has challenged the widespread belief that Bitcoin remains impervious to external threats. His recent statements highlight potential vulnerabilities in the network's legal infrastructure.

Szabo posted his concerns on X, stating that Bitcoin and other layer-1 networks possess a "legal attack" surface. This vulnerability allows governments and large corporations to disrupt operations through regulatory channels.

The cryptocurrency veteran dismissed the notion that Bitcoin functions as a completely autonomous system. He described the belief that blockchain protocols can withstand any governmental interference as "insanity." His position directly contradicts the common narrative of Bitcoin as an unstoppable financial network.

Szabo's perspective carries substantial weight in the cryptocurrency community. He developed the concept of Bit Gold in 1988, predating the creation of Bitcoin. His pioneering work on smart contracts established him as a foundational figure in the development of digital currency. Speculation has long circulated that Szabo might be Satoshi Nakamoto, the anonymous creator of Bitcoin. He has consistently denied these claims.

Legal Pressure Points in the Bitcoin NetworkThe Bitcoin pioneer identified specific targets for potential government action. Miners, node operators, and wallet service providers represent critical infrastructure points vulnerable to regulatory pressure. These entities operate within established legal frameworks, making them susceptible to coordinated enforcement actions.

Szabo focused his analysis on jurisdictions that maintain a strong rule of law. In these regions, authorities possess clear mechanisms to compel network participants into compliance. His warning centered on the potential for forced manipulation of network data.

The ability to insert or remove "arbitrary data" emerged as Szabo's primary concern. Regulators could mandate that network participants alter blockchain content. This scenario would undermine Bitcoin's core promise of immutable record-keeping.

The Ordinals and Runes ControversySzabo's comments connect to ongoing debates within the Bitcoin development community. The discussion revolves around non-financial content stored on the blockchain through Ordinals, Runes, and BRC-20 transactions. These protocols enable users to embed images, videos, and audio files directly onto the Bitcoin network.

Bitcoin Core and Bitcoin Knots represent two competing visions for the network's future. Bitcoin Knots has gained market share among node validators in recent months. This shift reflects growing dissatisfaction with Bitcoin Core's approach to network data.

The OP_RETURN function stands at the center of the controversy. Bitcoin Core developers implemented this feature, expanding the capacity for non-financial data on the blockchain. Critics argue that it enables "spam" transactions, which congest the network and inflate storage requirements.

Supporters argue that restricting data types contradicts Bitcoin's philosophy of being censorship-resistant. They view attempts to filter content as antithetical to the network's founding principles. The technical community remains divided on striking a balance between functionality and network efficiency.

Szabo's warnings drew immediate criticism from Bitcoin advocates. Chris Seedor, CEO of Bitcoin seed storage provider Seedor, challenged the assessment. He characterized Szabo's concerns as an overestimation of regulatory capabilities.

Seedor argued that Bitcoin's strength lies in minimizing technical vulnerabilities to coercion. He pointed to other resilient technologies as precedents. Protocols like PGP encryption and Tor remain operational despite government opposition. According to Seedor, these examples demonstrate the limits of regulatory power against decentralized systems.

Journalist

Posted: November 17, 2025

Key Takeaways
Is there pressure on Solana’s price?
A Solana whale recently exited a $4.71 million position at a loss, lending weight to the bearish pressure on the altcoin. 

Are SOL’s metrics leaning bearish too?
Yes, raising questions about whether Solana’s demand zone can continue to absorb this selling pressure.

Solana’s (SOL) price action has taken a big hit lately. At the time of writing, the altcoin’s large players seemed to be aggressively accumulating short positions at its trading price.

For instance – Whale DYzF92 dumped 33,366 SOL — valued at $4.71 million — despite locking in a $230,000 loss.

According to Lookonchain’s recent reports, the tokens were accumulated roughly seven months ago, making the sell-off a clear signal of shifting sentiment among major holders.

Could the demand zone absorb whales’ bearish pressure?
The whale’s exit adds more damage to an already fragile Solana market environment. According to AMBCrypto’s latest analysis, other large wallets have mirrored the same trend, stacking more short positions and signalling expectations of a near-term downturn.

In fact, CryptoQuant’s Spot average order size data hinted at a surging number of whale orders around the current trade. And, with the positions’ distribution metrics indicating short positions’ dominance, most of the accumulated orders may be likely from Solana bears.

Source: CryptoQuant

The coordinated whale activity has raised the question – Will this surge in short orders push SOL lower, or will the demand zone continue to hold the line?

On the daily chart, Solana’s price has been testing a well-defined demand zone around $14o – A strategic price level where buyers could step in consistently. The zone had previously triggered relief bounces, making it a critical battleground between bulls and bears.

If this zone absorbs whale-driven selling again, SOL could maintain its structure. However, if it fails, the downside could accelerate.

Source: TradingView

Long/Short ratio and ETF inflows signal growing bearish momentum
Additionally, Solana’s long/short ratio dropped below 1 too. Such a shift signifies clear short positions’ dominance as more traders may be betting on declining prices, rather than a bullish recovery.

A ratio below 1 often reflects a market leaning towards fear or cautious positioning. In Solana’s case, it would align perfectly with recent whale behaviour – Reinforcing its bearish indicators.

Source: Coinglass

At the same time, shrinking ETF inflows also send a cautionary signal to the anticipated reversal. Despite recording positive inflows over the last 24 hours, the overall trend of Solana has been steadily declining over the past few days.

Diminishing institutional interest at a time when the price action needs it is a cautionary sign to the token’s long-term holders.

Source: Coinglass

Despite the current bias, Solana has a history of surprising short sellers. Any strong reaction from the demand zone could trigger a temporary short squeeze.

For now, traders and investors are keenly watching whether bulls can reclaim control of the zone or if whales will dictate the next move for SOL.

8h05 ▪
4
min read ▪ by
Luc Jose A.

Summarize this article with:

As tension rises in the market, Bitcoin is about to cross a critical technical threshold : the “death cross”. This signal, feared by traders, occurs at a pivotal moment, at the intersection of a 25 % correction and an uncertain macroeconomic climate. While some see it as a classic bearish indicator, others recall it coincided with market lows. In this context, certainties waver, and each candlestick becomes a test for investor morale.

In brief

Bitcoin is approaching a “death cross,” a bearish technical signal feared by both traditional and crypto investors.
Despite its negative reputation, previous “death crosses” observed since 2023 have all coincided with local lows marking rebounds.
The market has corrected by 25 % since its October peak, bringing BTC below its annual entry price of $93,507.
The end of the US government shutdown, far from calming markets, triggered a new wave of decline, similar to a previous cycle in 2019.

The death cross signal : bearish indicator or turning point ?
Just a month after reaching a historic high above $126,000, BTC has dropped nearly 25 %, temporarily wiping out all of its gains since the start of the year.

Data from Glassnode reveal that short and long-term trend indicators are about to cross downward, a phenomenon known as a “death cross”. This configuration, where the 50-day moving average (MA50) falls below the 200-day moving average (MA200), is generally seen as a bearish signal.

Bitcoin’s 50-day moving average at $110,669 is now about to cross below the 200-day moving average at $110,459. This dynamic is often feared as it reflects weakening short-term momentum against the underlying trend.

However, historical data from the past two years challenges this pessimistic reading. Since the start of the 2023 bull cycle, each occurrence of a death cross has marked a local bottom rather than a prolonged collapse. Here are the previous noted cases :

September 2023 : the death cross coincided with a technical floor around $25,000 ;

August 2024 : amid the yen carry trade crisis, Bitcoin bounced back after hitting $49,000 ;

April 2025 : in a context of uncertainties related to Trump’s tariff policies, BTC briefly fell below $75,000 before rising again ;

November 2025 : the Bitcoin price flirts with $94,000, and some analysts already see the beginnings of a new rebound just before the expected crossover.

This fourth crossover could once again play the role of a “bull trap” rather than a harbinger of a crash.

The fragile balance of the market
The current situation is not just a technical reading. The macroeconomic context acts as a catalyst for this volatility.

The end of the US government shutdown, which occurred on November 12 after 43 days of halt, paradoxically triggered a 10 % drop in BTC within a few days. This type of reaction had already been observed in January 2019 when Bitcoin declined by 9 % in the five days following the resumption of government activities.

Meanwhile, another factor weighs on the upward momentum : profit-taking behaviors among whales. It is not a panic movement but a classic pattern of the end of a bull cycle.

Such a gradual increase reflects growing distribution pressure from older holders, a typical pattern of profit-taking at the cycle’s end, and not a sudden exit by whales. This nuance is essential because it shows the observed movements are less related to a confidence crisis and more to tactical risk management by experienced investors.

As explained Matt Hougan, CIO of Bitwise, “the fundamentals remain strong… I believe 2026 will be a good year”.

In the medium term, this combination of factors raises questions about the validity of the traditional four-year crypto cycle. Despite broader institutional adoption, the rise of Bitcoin ETFs and a Trump administration seen as pro-crypto, the market shows signs of fragility. To succeed, the market will first have to navigate this phase of instability.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Luc Jose A.

Diplômé de Sciences Po Toulouse et titulaire d'une certification consultant blockchain délivrée par Alyra, j'ai rejoint l'aventure Cointribune en 2019.
Convaincu du potentiel de la blockchain pour transformer de nombreux secteurs de l'économie, j'ai pris l'engagement de sensibiliser et d'informer le grand public sur cet écosystème en constante évolution. Mon objectif est de permettre à chacun de mieux comprendre la blockchain et de saisir les opportunités qu'elle offre. Je m'efforce chaque jour de fournir une analyse objective de l'actualité, de décrypter les tendances du marché, de relayer les dernières innovations technologiques et de mettre en perspective les enjeux économiques et sociétaux de cette révolution en marche.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017,
aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy,
our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a
rigorous Review Methodology when evaluating exchanges and tools. From emerging
blockchain projects and coin launches to industry events and technical developments, we cover
all facets of the digital asset space with unwavering commitment to timely, relevant information.

Shiba Inu has now been added to the  “Green List” of pre-approved crypto assets for Japan. This puts the token alongside Bitcoin and Ethereum and sets the token for possible tax relief.

Shiba Inu Gets Green List Approval In Japan
Japan’s Financial Services Agency (FSA) has added Shiba Inu to its Green List. The move places SHIB as one of the recognized digital assets in the country. This comes when the government is reportedly considering slashing its crypto capital gains tax rate from 55% to 20%.

$SHIB has officially joined Japan’s “Green List,” standing beside $BTC and $ETH.

A proposed tax drop from 55% → 20% could make this a huge catalyst.

Read about it below 👇🏼 https://t.co/0PUBE5TIvJ

— Shib (@Shibtoken) November 17, 2025

Currently, Japanese crypto traders must report their gains as miscellaneous income. But under the FSA’s new framework, profits from 105 approved assets could soon be taxed as a flat rate. That could happen as early as 2026.

The approval of Shiba Inu also comes after assessment from Japan’s regulators. Compliance with standards by SHIB earns it a position that puts it next to Bitcoin, Ethereum, and just 27 other crypto assets.

The token fulfilled this condition since it is listed on at least eight licensed exchanges. Usually, he minimum needed to be considered is three.

The Green List was created in 2022 to simplify the approval process for trusted tokens. Inclusion on the list puts the meme token as a credible crypto project both for regulators and institutional investors.

The regulatory commission has been making some changes to its crypto ecosystem. The FSA last month put forward a proposal for a legal framework in the classification of crypto assets like traditional securities. This would make insider trading criminal and make market operations more transparent.

SHIB Set to Benefit From 20% Tax Reform
The country’s planned tax reform could lower costs for crypto traders. This change would help Japan match other developed countries. For instance, Germany does not tax long-term crypto gains at all. 

Meanwhile, there are claims that U.S President Trump could remove the tax for crypto firms in the country

RUMOR: 🚨

🇺🇸 President Trump to declare a 0% tax for crypto companies based in the U.S. starting in 2026. pic.twitter.com/fg3eFuhE1Q

— CEO (@Investments_CEO) November 15, 2025

Finance Minister Katsunobu Kato has stated that regulators are almost done finalizing the policy. In other economic news, Japan’s government announced a $113 billion stimulus package. This move would see tax removed totally for some industries. These could lower living costs for citizens in the country.

Meanwhile, a team member of the meme coin shared that the Shiba Inu project is targeting some  Asian markets. The team is especially looking into South Korea and China.

Ethereum has once again fallen under pressure as its price slipped toward the critical $3,000 mark. After failing to sustain momentum above $3,250, ETH extended its decline and is now showing signs of continued weakness across lower timeframes.

Bitcoin price slid to its lowest level in over six months on Monday, weighed down by a wave of liquidations and ongoing outflows from its spot ETFs.

Summary

Bitcoin price is down over 10% in the last 7 days.
Over $240 million has been liquidated from BTC futures market.
Bitcoin has confirmed a death cross on the daily chart.

According to data from crypto.news, the world’s largest crypto asset was trading around $95k last check on Nov. 17, morning Asian time. It fell below $94,000 support to an intraday low of $93,029 earlier in the session, the lowest recorded since April 12 this year. 

At its current price, Bitcoin (BTC) is down 10.6% in the past 7 days and 24.6% below its year-to-date and all-time high of $126k reached about a month ago.

Bitcoin price continued its downtrend on Monday as derivatives traders appear to be de-risking their positions amid decreasing odds that the Federal Reserve will announce another rate cut this year. Such a shift in expectations tends to spark risk-off sentiment across broader markets, including crypto.

According to the CME FedWatch Tool, the odds of a 25 basis point rate cut in December have fallen to 43.9%, while a separate prediction market on Polymarket shows the probability at just 46%, sharply down from over 80% at the start of November.

In the past 24 hours, around $243 million worth of positions were liquidated across the Bitcoin futures market, with long positions making up the majority at $136.6 million.

Major liquidation events unfold when leveraged positions are forcibly closed by the exchange due to insufficient margin, which can lead to cascading sell pressure, like the one seen last month when over $20 billion was flushed out of the market.

Waning demand from institutional investors has also been another major factor weighing on Bitcoin’s recent price action. The 12 spot Bitcoin ETFs in the United States have recorded more than $2.3 billion in net outflows over the past two weeks, data from SoSoValue show.

Sustained capital flight from the spot ETF market is a sign of weak confidence among large investors and may continue to pressure Bitcoin’s price over this week, especially if broader macro uncertainty persists.

Bitcoin price confirmed a death cross
The daily chart shows that Bitcoin price has confirmed a death cross, a very bearish pattern in technical analysis that forms when the 50-day simple moving average crosses below the 200-day simple moving average. Historically, Bitcoin has often seen extended downside pressure in the months following the appearance of such a pattern on the chart.

Bitcoin price has confirmed a death cross on the daily chart — Nov. 17 | Source: crypto.news
Bitcoin price also closed its weekly candle below the 50-day exponential moving average last week for the first time since August 2023, a sign that momentum may be shifting in favor of the bears.

The Aroon Up indicator stood at 92.86% while the Aroon Down was at 0%, further confirming that bears were in control of the market.

Bitcoin Aroon chart — Nov. 17 | Source: crypto.news
For now, the $93,770 to $94,000 region looks like the next key support zone for Bitcoin, a drop below which could trigger losses toward the $90,000 psychological support or even lower.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

VISA Transactions Could Soon Flow Through Ripple’s Interledger ProtocolA recent report, highlighted by renowned crypto observer SMQKE, reveals a potential breakthrough in payments infrastructure that VISA transactions may soon be integrated with Ripple’s Interledger Protocol (ILP). 

Therefore, this development could mark a significant milestone in bridging traditional financial systems with blockchain-based payment networks.

Ripple’s ILP, a protocol designed for seamless, cross-ledger payments, enables instant transfers across different payment networks without relying on intermediaries. 

By connecting traditional financial rails like VISA to ILP, financial institutions could achieve faster, more efficient, and cost-effective transaction processing. The integration promises to reduce the friction and delays that often plague cross-border payments, which currently rely on legacy systems such as SWIFT.

The report indicates that VISA could leverage Ripple’s Interledger Protocol to enable near-instant, transparent payments across banks, digital wallets, and financial networks, offering faster fund access, lower fees, and a seamless payment experience for businesses and consumers.

Notably, Ripple’s Interledger Protocol is built for seamless interoperability, enabling real-time connections across diverse ledgers. This positions VISA to modernize its payment infrastructure while maintaining regulatory compliance and operational reliability, bridging traditional finance and digital assets.

Beyond speed and efficiency, integrating Ripple’s ILP with VISA could bridge traditional finance and blockchain, creating a seamless hybrid ecosystem. This move could drive mainstream adoption of digital currencies, positioning ILP as a key infrastructure for global payments.

Therefore, the report highlights the rising convergence of traditional finance and decentralized networks. Integrating VISA transactions with Ripple’s ILP could usher in a new era of cross-border payments, delivering unmatched speed, transparency, and scalability.

XRP Eyes $5–$8 as Strong Support Zone Bolsters Institutional ConfidenceAccording to prominent market analyst Crypto Patel, XRP has established a decisive support zone between $1.85 and $2, signaling a robust foundation for both retail and institutional investors. This range, Patel notes, represents a strong liquidity and accumulation base, creating a favorable environment for potential price expansion in the months ahead.

Source: Crypto PatelXRP’s $1.85–$2 support zone is proving pivotal with the current price being $2.27. Historically, areas of high liquidity and concentrated institutional accumulation absorb selling pressure and anchor markets during volatility. 

As Crypto Patel notes, XRP’s consolidation here reflects strong investor confidence and positions the coin for potential structural growth.

XRP continues its bullish momentum across multiple timeframes, with strong trading volumes and clear institutional accumulation signaling strategic positioning. Analyst Patel suggests that if the $1.85–$2 support holds, XRP could see a structural surge toward $5–$8, representing substantial upside potential.

Therefore, XRP’s $1.85–$2 support zone is more than a floor, it signals strong institutional backing, deep liquidity, and bullish momentum. If trends hold, a structural move toward $5–$8 is well-supported by market dynamics and investor activity, reinforcing XRP’s upward trajectory.

ConclusionIntegrating VISA transactions with Ripple’s Interledger Protocol could transform payments, combining traditional network reliability with blockchain’s speed, transparency, and interoperability. This leap promises a faster, more efficient ecosystem and marks a major step toward a truly connected global financial landscape.

On the other hand, XRP’s $1.85–$2 support zone highlights strong institutional interest and deep liquidity. With bullish momentum intact, this level not only defends current valuations but also positions XRP for a potential surge toward $5–$8.

The digital assets sector remains weak as Bitcoin erases 2025 gains after its latest dip toward the $93,000 vicinity. While altcoins display substantial bearishness, ASTER stayed above the $1 psychological mark after gaining more than 6% the last 24 hours. The altcoin's decouple comes as the perpetual decentralized exchange launches its largest trading competition.

The Dogecoin price recently spiraled lower, mirroring Bitcoin’s sharp fall below $100k and the broader crypto market fall. The mood shifted from optimism to caution almost overnight as whale activity picked up, igniting a violent sell-off. A staggering $700 million DOGE flowed from large holders, intensifying downward momentum and sparking jitters among retail traders. 

As prices smashed through the crucial $0.16466 level, technical alarms became undeniable, confirming a bearish break. With nerves stretched, investors are now questioning: will DOGE find its footing soon, or will it go deeper into lows? If you are one of them, then this price analysis is a must-read for you. 

DOGE Price AnalysisChecking DOGE’s four-hour chart, the action paints a tale of persistence and pressure. The Doge price stumbled under the 78.6% Fibonacci retracement at $0.16466 and now trades at $0.1619, marking a daily dip of 0.69% and a week-long slide of 10.56%. Successively, technical signals remain bleak, with the RSI dipping to 45.99 and hugging oversold territory.

That being said, the support now lines up at the October low of $0.1525. Should bears overpower this level, the next landing spot sits at $0.14. Each retest of these lines has increased risk for bulls, as stop-losses below the Fibonacci support fuel further downward momentum. The 200-day SMA, high above at $0.20925, justifies how far DOGE’s price has retreated from its medium-term trend.

For price watchers hoping for relief, keep your eyes on $0.171. This point marks the best chance for a bounce. A daily close above can trigger short-term bullish momentum and drive a swift run toward $0.18766. However, unless buyers flood in to reclaim lost ground, the bias stays firmly bearish.

If the next support gives way, downside could escalate rapidly to $0.14. Contrarily, a breakout above $0.171 could shift sentiment and invite quick gains back into the range. When to expect targets? The speed of moves in DOGE tends to surprise, but based on current momentum, a break to $0.1525 or a rebound to $0.171 could play out in the next 3 to 5 sessions.

FAQsWhere is Dogecoin’s next support if selling continues?

The next major support is $0.1525. If that fails, DOGE could test $0.14 quickly.

Can Dogecoin price rally soon?

Relief depends on reclaiming $0.171 with a daily close. Without strong buying, rallies may be short-lived.

Is Dogecoin oversold now?

Yes, the RSI indicates oversold conditions, but there’s no bullish divergence yet to hint at a reversal.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Key NotesAnalysts warn of a possible decline to $83,500.More than 10,000 BTC, worth $1 billion, moved to exchanges in the past 72 hours.Major investors like Robert Kiyosaki and Michael Saylor signal long-term confidence.
After losing the crucial $100,000 support, Bitcoin’s price has extended losses, testing lows below $93,000 on Monday, Nov. 17.

Gold buff Peter Schiff took this moment to highlight Gold’s outperformance as the yellow metal regains $4,100 levels. Experts believe that if the sell-off continues,

BTC
$95 607

24h volatility:
0.5%

Market cap:
$1.91 T

Vol. 24h:
$79.15 B

price can drop further to $83,500.

In early Asian trading, gold is already back above $4,100 while Bitcoin is struggling to hold $93,000. Bitcoin is now down 26% from its high. But in terms of gold, the bear market is far more ferocious, with Bitcoin down 39%. Sell Bitcoin now and buy gold before you get mauled.

— Peter Schiff (@PeterSchiff) November 16, 2025

Sell Bitcoin Now and Buy Gold, Says Peter Schiff
Earlier today, Bitcoin’s price took a dive below $93,000, with 24-hour liquidations soaring to $243 million, according to Coinglass data. With BTC eroding all of its 2025 gains, critics like Peter Schiff have stepped up fresh attacks on the largest crypto.

Highlighting Gold’s dominance over BTC, Schiff said that the yellow metal has resumed its upward momentum, trading back above $4,100 during early Asian hours, while Bitcoin is struggling to maintain levels near $93,000. The BTC sell-off has intensified amid strong Bitcoin ETF outflows last week.

Peter Schiff added that Bitcoin is now down 26% from its recent peak. He emphasized that the decline is even more severe when measured against gold.

According to him, Bitcoin has fallen 39% in gold terms, signaling a “far more ferocious” bear market relative to the precious metal. “Sell Bitcoin now and buy gold before you get mauled,” said Schiff in his recent message on X platform.

Market experts believe there’s been a growing divergence between BTC’s price and Gold since the massive $19.2 billion crypto market liquidation on October 10.

Over the past month, gold has outperformed Bitcoin by roughly 25 percentage points, reversing several months of strong positive correlation between the two assets.

Analysts at The Kobeissi Letter noted that sentiment and price dynamics changed sharply after the October 10 liquidation event. They added that the divergence is primarily due to extremely high leverage levels and liquidation pressure.

Bitcoin and Gold Decoupling | The Kobeissi Letter

Senior Bloomberg analyst Eric Balchunas has come to Bitcoin’s defense amid major flak amid underperformance against Gold. He wrote:

Did any bitcoiners complain last year when btc was up 122%, which was 5x SPY, GLD? Was anyone like 'wait, btc's historical perf relative to risk assets says it shouldnt be this high, this is bad!' No, you loved the extra excess, double dip, and so this year you get nothing,… pic.twitter.com/utxLLCUR6G

— Eric Balchunas (@EricBalchunas) November 15, 2025

Experts See BTC Price Sell-off to $83,500
Crypto analyst Ali Martinez reports that Bitcoin has broken out of its trading channel. This has further increased the probability of a BTC price fallout to $83,500.

At the same time, Martinez highlights rising selling pressure, noting that more than 10,000 BTC, nearly $1 billion, have flowed into crypto exchanges over the past 72 hours. The surge in inflows signals waning investor sentiment in current market conditions.

More than 10,000 Bitcoin $BTC, almost $1 billion, have hit crypto exchanges in the past 72 hours! pic.twitter.com/3kwwzLMKH0

— Ali (@ali_charts) November 16, 2025

Amid this current sell-off, veteran investor Robert Kiyosaki said he plans to increase his Bitcoin holdings once the ongoing market selloff concludes. On the other hand, big market players continue to show confidence in BTC.

While sharing his Bitcoin buying tracker with orange dots, Michael Saylor hinted at additional BTC purchases, calling it a “Big Week” ahead. Thus, he has debunked the theory of Strategy selling Bitcoins from its holdings.

₿ig Week pic.twitter.com/a27eg6Kw4v

— Michael Saylor (@saylor) November 16, 2025

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Bitcoin News, News

Bhushan is a FinTech enthusiast and holds a good flair in understanding financial markets. His interest in economics and finance draw his attention towards the new emerging Blockchain Technology and Cryptocurrency markets. He is continuously in a learning process and keeps himself motivated by sharing his acquired knowledge. In free time he reads thriller fictions novels and sometimes explore his culinary skills.

Bhushan Akolkar on X

U.S. spot Bitcoin exchange-traded funds experienced significant capital withdrawals during the week of November 10 to 14. The funds recorded net outflows totaling $1.11 billion, marking the third straight week of negative flows for the investment vehicles.

Data from SoSoValue reveals that institutional appetite for Bitcoin exposure through ETFs has cooled considerably. The sustained outflows represent a notable shift in market sentiment following months of strong inflows into these products.

BlackRock and Grayscale Lead Outflow WaveBlackRock's IBIT fund witnessed the largest single-week outflow among all spot Bitcoin ETFs. The fund saw $532.41 million exit during the reporting period. Despite this substantial withdrawal, IBIT maintains a cumulative net inflow of $63.79 billion since its inception.

Grayscale Bitcoin Mini Trust recorded the second-largest outflow for the week. The fund registered nearly $290 million in net withdrawals by November 14. The fund's historical net inflow stands at $63.79 billion as of the latest reporting date.

Grayscale Bitcoin Mini Trust(BTC), Source: SoSoValue

Current figures show the combined net asset value of all spot Bitcoin ETFs stands at $125.34 billion. These investment products now represent 6.67% of Bitcoin's total market capitalization, indicating their substantial presence in the broader cryptocurrency ecosystem.

Industry Experts Weigh In on Market DynamicsSimon Gerovich, CEO of Japanese Bitcoin treasury firm Metaplanet, offered a perspective on the distinction between ETFs and treasury companies. He emphasized that ETFs provide static exposure to Bitcoin rather than active accumulation strategies.

"A BTC ETF provides fixed exposure to Bitcoin," Gerovich explained through social media. He noted that ETF holdings remain constant unless new capital flows into the funds. This contrasts with corporate treasury strategies that actively accumulate Bitcoin regardless of market conditions.

Przemysław Kral, CEO of European cryptocurrency exchange zondacrypto, addressed the immediate market implications. He highlighted concerns about the liquidity conditions in cryptocurrency markets over the weekend.

"We must beware of weekend liquidity, which is always thinner with fewer active traders letting each forced sale move the market more," Kral stated. He suggested that long-term investors might view the current environment as an accumulation opportunity. Short-term traders, however, face difficulties in predicting recovery timing.

The substantial ETF outflows have coincided with downward pressure on Bitcoin's price. Bitcoin traded near $95,647 at the time of reporting, reflecting a 0.32% decline over 24 hours. The price level represents a six-month low for the leading cryptocurrency.  

BTC price action in the last 24 hours, Source: CoinMarketCap

Cryptocurrency markets experienced widespread liquidations totaling $617.45 million within a 24-hour period. Bitcoin accounted for $243.56 million of these forced position closures. Ethereum followed with $169.06 million in liquidations during the same timeframe.

XRP analysts track key support, bull flag patterns, rising scam alerts, and growing interest in Evernode amid shifting market activity.

Investor interest is shifting. While Evernode gains momentum in the ecosystem, XRP faces mixed signals on both short and long timeframes.

Crypto trader WillyWonkaXRP commented, “I’ve been focusing on Evernode because frankly speaking it’s got MAJOR legs,” adding that he’s stepping back into Ripple coverage to counter misinformation.

Evernode is a Layer-2 smart contract solution operating on the XRP Ledger (XRPL). It runs on the Xanau sidechain and allows developers to build dApps using various programming languages on a scalable network of hosts.

XRP Moves Within Ascending Channel
XRP is holding inside an ascending channel on the chart. The price recently tested the lower edge of the structure and bounced. This area has acted as support multiple times and continues to do so. As long as the asset stays above this trendline, the pattern remains valid.

Source: WillyWonkaXRP/X
Over the past week, XRP has dropped more than 8%, with a daily decline of less than 1%. A key observation is the long lower wick formed near the support line. This suggests buyers are active in that zone. If the current structure continues, a move toward $2.8 to $3 could follow. A breakout above this range may push the price higher, with some projections between $6 and $9.

Bull Flag Above 2021 Highs
Analyst ChartNerd pointed out a possible bull flag on the longer timeframe.

“$XRP: Zooming into the fractal, the bull flag/pennant structure holding above the 2021 highs should not be ignored,” the analyst shared.

The support is around $2, which aligns with the previous cycle’s peak.

You may also like:

After XRPC, the Race Is On: Which XRP ETF Will Hit the Market Next?

Canary’s XRP ETF (XRPC) Launch Successful: Here’s What Happened on Day 1

XRP Leads the Fear Trade as BTC and ETH Sentiment Weakens

The flag pattern formed after a sharp move up earlier this year. Since then, XRP has been trading within a narrowing range. This type of consolidation often leads to a continuation move. The estimated breakout target from this setup is $20, based on the height of the flagpole.

Short-Term Resistance and Support Levels
According to CRYPTOWZRD, XRP is trading below $2.25, which is now a key short-term resistance. A move toward $2.41 could trigger a short setup if the price fails to hold that level. On the other hand, if XRP breaks and holds above that line, it may open the door for further upside.

Notably, the next support level on the lower time frame is $2.08. Until the chart forms a more defined structure, the trading range remains uncertain. The same analyst also noted that XRP/BTC strength may return if Bitcoin dominance continues to fall, possibly helping Ripple’s token reach $2.75.

Scam Warnings and Market Activity
Ripple has issued new warnings on social media about scams targeting XRP holders. They follow the recent Swell event and coincide with the introduction of a spot XRP ETF in the US. The attention from these events may be drawing out new fraud attempts.

Meanwhile, large wallet activity shows consistent selling from major XRP holders. These movements have raised some questions within the community, especially during a period of broader market volatility. Traders are monitoring wallet flows and exchange data as the market looks for a clear direction.

Tags:

Bitcoin’s sharp drop toward $93,000 triggered fresh debate across the crypto space, with some analysts and executives blaming a mix of whale selling, ETF outflows, tightening liquidity, and rising geopolitical uncertainty. At the same time, Rich Dad Poor Dad author Robert Kiyosaki says he’s unfazed by the downturn, and argued that a global cash shortage—not fading conviction—is driving the sell-off. He expects governments to eventually respond with massive money printing, which he believes will ultimately boost the value of assets like Bitcoin, gold, and Ethereum.

Bitcoin Slump Raises QuestionsBitcoin’s slide toward $93,000 over the weekend led to fresh debate across the industry, and executives and analysts are pointing to a mix of structural and macroeconomic factors driving the downturn. The drop marked a year-to-date low and dragged the overall crypto market capitalization down from $3.7 trillion to $3.2 trillion in just one week.

Crypto market cap over the past month (Source: CoinMarketCap)

Industry leaders say the pullback isn’t the result of a single shock, but rather a confluence of pressures hitting simultaneously. Ryan McMillin, CIO of Merkle Tree Capital, recently said in an interview that long-term Bitcoin holders seem to be “finally cashing in after an extraordinary run,” releasing large amounts of old supply into the market just as liquidity thins out. He added that spot Bitcoin ETFs, which were major accumulators earlier in the year, have now flipped to net outflows, removing one of the market’s most reliable sources of demand at a time when global sentiment grew more risk-averse and expectations for rate cuts have been delayed.

Binance Australia and New Zealand GM Matt Poblocki said that the volatility proves that crypto is still deeply tied to global macro and political events. Geopolitical tensions, rate-sensitive tech valuations and uncertainty across major economies continue to weigh on risk assets broadly. Banxa CEO Holger Arians agreed, and pointed out that markets have been running hot while the world faces multiple unresolved crises, making a risk-off correction “almost inevitable” after a year of sustained optimism.

Other executives shared even more theories. Bitwise CEO Hunter Horsley suggested that the industry’s longstanding four-year cycle narrative may be fueling self-fulfilling panic among traders. Fundstrat’s Tom Lee speculated that market makers with weakened balance sheets may be facing targeted liquidity stress, which could potentially accelerate the downturn.

Still, many analysts argue that the correction is not only normal, but also healthy. Poblocki explained that retail investors are not abandoning the market, but are rotating into Bitcoin and Ethereum rather than exiting entirely, which could be a sign of improving investor maturity. ETF activity, while softer, has not seen major redemptions, and institutional involvement is also still high.

Arians added that despite the price weakness, crypto’s underlying fundamentals continue to improve, pointing to rising stablecoin volumes, sustained on-chain activity and growing developer momentum. He argued that the infrastructure now being built is laying the groundwork for the next expansion cycle.

Overall, while fear has resurfaced, the consensus among industry leaders is that the long-term trajectory is still intact, and that the current slump may ultimately prove to be another temporary chapter in crypto’s evolution.

Kiyosaki Holds Firm as Markets DropMeanwhile, Robert Kiyosaki, the author of Rich Dad Poor Dad, told his followers on X that he has no plans to sell his Bitcoin or gold. While many investors are reacting to sharp price drops, Kiyosaki argued that the true driver behind the current sell-off is not fear, speculation, or shifting narratives, but something far more fundamental — a global shortage of cash.

In a Saturday post, he said that “the everything bubbles are bursting,” and framed the decline across markets as a function of liquidity stress rather than weakened long-term conviction. He agreed with economist Lawrence Lepard’s thesis that governments overwhelmed by debt will eventually be forced into large-scale money creation to stabilize their economies. According to Kiyosaki, this upcoming phase — which he refers to as “The Big Print” — will severely devalue fiat currencies while boosting hard assets like gold, silver, Bitcoin, and Ethereum.

Kiyosaki added that many people currently selling are doing so because they need cash, not because they have lost faith in their investments. For those who truly do require liquidity, he suggested selling a portion of their assets but also explained that panic selling due to market volatility is rarely rational. He reiterated that while he won’t be selling, he understands “many need cash.”

In a follow-up post, Kiyosaki again reaffirmed his long-term bullishness on Bitcoin. He said he intends to buy more once the market finishes correcting, and reminded his audience that Bitcoin’s fixed supply of 21 million coins is still one of its strongest value propositions. 

He also used the moment to encourage followers to build “Cashflow Clubs,” based on his educational board game, and argued that group learning can help people avoid costly mistakes during turbulent market periods.

Top crypto stocks will be under pressure on Monday as Bitcoin and most altcoins continue their downtrend. The Bitcoin price has crashed to $95,000, down by about 25% from its highest point this year.

November 17, 2025 01:52 ET

 | Source:

Mesoblast Limited

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.

Mesoblast CEO Dr Silviu Itescu said: “We are very pleased to have Jim join us at Mesoblast. His deep cross functional financial expertise and knowledge of US markets fills a key senior leadership position as we transition to a mature commercial organization. Jim’s extensive experience will provide Mesoblast with the financial leadership required as it commercializes Ryoncil® and looks forward to label expansion. His skillsets will complement those of Andrew Chaponnel, our Head of Finance, implementing robust financial controls, reporting and governance related to revenue forecasting, financing, and capital allocation.”

Jim has had global responsibility overseeing Corporate and Business Unit finance, Reporting, Internal Controls and Accounting Operations at Actavis plc which subsequently acquired Allergan plc prior to its acquisition by AbbVie Inc. Jim created a world-class financial budgeting and forecasting process to track business performance and trends, and developed financial tools and analyses supporting a range of corporate activities including Business Strategy and Corporate Development, integrating international business acquisitions and managing activities for transactions of nearly $10 billion. During his tenure, Actavis had proforma revenues of over $8 billion. Previously, Jim built a finance team overseeing all supply chain and revenue management for Nycomed, a private equity owned company with $750 million revenues that was acquired by Sandoz for $1.5 billion. Jim’s recent CFO roles included NASDAQ-listed biopharmaceutical company Cognition Therapeutics, Inc., overseeing the company’s successful initial public offering, and at dual-listed Finnish biotechnology company Faron Pharmaceuticals, Ltd. He has also held finance roles at Bristol-Myers Squibb (BMS). Jim is a certified public accountant and previously worked at PriceWaterhouseCoopers in New York and Washington DC.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036

Media – Global 
Allison Worldwide 
Emma Neal 
T: +1 603 545 4843 
E: [email protected]

Media – Australia 
BlueDot Media 
Steve Dabkowski 
T: +61 419 880 486 
E: [email protected]

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS

November 17, 2025 02:00 ET

 | Source:

Pulsar Helium

CASCAIS, Portugal, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium development company, is pleased to announce that Thomas Abraham-James, Pulsar’s CEO, and Dr. Peter Barry, the Company’s Scientific Helium-3 Advisor, will provide a live investor presentation via Investor Meet Company on November 25, 2025, at 4:30 pm GMT (08:30 am PST, 10:30 am CST, 11:30 am EST).

The presentation will begin with a fifteen-minute virtual site visit from the Company’s flagship Topaz Project in Minnesota, where Thomas Abraham-James and other key members of the operational team will highlight ongoing drilling processes and key company updates, followed by a live Q&A via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until November 24, 2025, at 09:00 am GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free to meet Pulsar Helium Inc. via:

https://www.investormeetcompany.com/pulsar-helium-inc-1/register-investor

Investors who already follow Pulsar Helium Inc. on the Investor Meet Company platform will automatically be invited.

On behalf Pulsar Helium Inc.
“Thomas Abraham-James”
President, CEO and Director

Further Information:

Pulsar Helium Inc.
[email protected]
+ 1 (218) 203-5301 (USA/Canada)
+44 (0) 2033 55 9889 (United Kingdom)
https://pulsarhelium.com
https://ca.linkedin.com/company/pulsar-helium-inc.

Yellow Jersey PR Limited
(Financial PR)
Charles Goodwin / Annabelle Wills
+44 777 5194 357
[email protected]

Strand Hanson Limited
(Nominated & Financial Adviser, and Joint Broker)
Ritchie Balmer / Rob Patrick / Richard Johnson
+44 (0) 207 409 3494

OAK Securities*
(Joint Broker)
Richard McGlashan / Mungo Sheehan
+44 7879 646641 / +44 7788 266844
[email protected] / [email protected]
*OAK Securities is the trading name of Merlin Partners LLP, a firm incorporated in the United Kingdom and regulated by the UK Financial Conduct Authority.

About Pulsar Helium Inc.

Pulsar Helium Inc. is a publicly traded company quoted on the AIM market of the London Stock Exchange and listed on the TSX Venture Exchange with the ticker PLSR, as well as on the OTCQB with the ticker PSRHF. Pulsar's portfolio consists of its flagship Topaz helium project in Minnesota, USA, and the Tunu helium project in Greenland. Pulsar is the first mover in both locations with primary helium occurrences not associated with the production of hydrocarbons identified at each.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

So What: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=19024https://rosenlegal.com/submit-form/?case_id=41168or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On August 7, 2025, before the market opened, the company issued a press release entitled "Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps." The release stated that Tandem Diabetes had "announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery."

On this news, Tandem Diabetes' stock fell 19.9% on August 7, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

The Tencent Holdings shareholder anticipates a boost to first-half earnings from increased profitability at the Chinese technology giant and at its own e-commerce business.

IXICO PLC (LSE:IXI, OTC:PHYOF) has secured a contract worth more than £3.5 million to support a major phase III clinical trial in Huntington’s Disease, marking a significant commercial step for the neuroscience data specialist.

The London-based group said the four-year agreement, signed with a global pharmaceutical company, will see it provide imaging services for the worldwide study.

Phase III trials are the final stage before a company seeks regulatory approval for a new treatment, making them the most extensive and costly part of drug development.

Huntington’s is a rare inherited disorder that steadily damages nerve cells in the brain.

It affects movement, thinking and behaviour, and has no cure. Research activity in the field has increased in recent years as pharmaceutical companies explore new approaches to slow or modify the course of the disease.

IXICO has long positioned itself in this niche. Its platform uses artificial intelligence to analyse brain scans and measure subtle changes in neurological conditions, a capability that has helped it carve out a role in Huntington’s studies.

The company said its expertise in biomarkers, clinical trial operations and image analysis has made it a regular partner in research programmes.

Bram Goorden, chief executive of IXICO, said: “This is an important contract in terms of value and trial stage that further cements IXICO’s position in the field.

"We are very proud to continue our support of the HD community, working with HD research consortia and pharmaceutical partners towards breakthrough treatments for patients in this devastating disease.”

He added that increased investment from the sector into rare neurological disorders was encouraging, noting his optimism that such efforts could lead to meaningful advances.

The deal also extends the company’s recent progress under its “Innovate, Lead, Scale” strategy, which focuses on expanding its role in global neuroscience drug development.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in UPS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs"). The additional ADSs are expected to be delivered on November 18, 2025.

Following the exercise in full of the Underwriters' Option, the total number of ADSs issued in the Offering will amount to 44,805,193, resulting in gross proceeds for the Company of approximately $172.5 million (€149.0 million1) and the estimated net proceeds of the Offering, after deducting underwriting fees, commissions and estimated expenses payable by the Company, will be approximately of $161.2 million (€139.3 million1).

The Company intends to apply the net proceeds from the sale of Additional ADSs on a pro rata basis to the use of proceeds identified with respect to the base offering.

The offering price of $3.85 per ADS and Additional ADS (corresponding to €3.33 per ordinary share based on the exchange rate of €1.00 = $1.1576 as published by the European Central Bank on November 12, 2025) is equal to the volume-weighted average price of the share of the Company on the regulated market of Euronext in Paris ("Euronext") for the last trading session preceding the pricing date of the Offering, less a discount of 0.89%. The offering price was determined by the Chief Executive Officer in accordance with a sub-delegation of powers from the Company’s Board of Directors (Conseil d'Administration) on October 27, 2025, pursuant to the 25th resolution of the Company’s combined shareholders’ meeting held on May 22, 2025

The Company’s ADSs are listed on the Nasdaq Global Market under the ticker symbol "IVA" and the Company’s ordinary shares are listed on Euronext under the symbol "IVA".

The exercise of the Underwriters' Option is part of stabilization activities carried out since the announcement of the Offering. The stabilization period is now closed.

A shelf registration statement on Form F-3 (including a prospectus) relating to the Company’s securities was filed with the Securities and Exchange Commission (the "SEC") in the United States on October 14, 2025 and became effective on November 3, 2025. The Company has also filed with the SEC a final prospectus supplement (and accompanying prospectus) relating to and describing the terms of the Offering (the "Final Prospectus Supplement"). These documents may be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, a copy of the Final Prospectus Supplement (and accompanying prospectus) may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; or from Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401 or by email at [email protected].

The Offering was not subject to a prospectus requiring an approval of the French Financial Markets Authority (Autorité des Marchés Financiers) (the "AMF"). In accordance with Article 1(5) (ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the "Prospectus Regulation"), the Company has filed with the AMF a document containing the information set out in Annex IX of the Prospectus Regulation (the "Information Document") considering that the Offering represents a dilution above 30% of the current share capital of the Company. A copy of the Information Document is available on the Company’s website (www.inventivapharma.com). 

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com   

Contacts 

Important Notice

This press release contains certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva’s expectations regarding its ability to consummate the Offering, and the timing, size and use of proceeds of the Offering, future activities, expectations, plans, growth and prospects of Inventiva, and the absence of material adverse events. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", "designed", "hopefully", "target", "potential", "opportunity", "possible", "aim", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including the completion of financial closing procedures, that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, that the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, on the expected timing or at all, and whether, when and to what extent the dilutive instruments may be exercised, and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or additional amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva’s ability to identify additional products or product candidates with significant commercial potential, Inventiva’s expectations with respect to its pipeline prioritization plan and related workforce reduction, including the timing, potential benefits, expenses and consequences relating thereto, Inventiva’s ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva’s ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil, and natural catastrophes, uncertain financial markets and disruptions in banking systems. Given the risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2024 filed with the Autorité des Marchés Financiers on April 15, 2025, the interim financial report for the six months ended June 30, 2025 published on September 29, 2025 and the Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the "SEC") on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption "Risk Factors", and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Disclaimers 

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

France

The securities offered as part of the Offering have not been and will not be offered or sold to the public in France (except for public offerings defined in Article L.411-2 1° of the French Monetary and Financial Code).

The securities offered as part of the Offering may only be offered or sold in France pursuant to Article L. 411-2 1° of the French Monetary and Financial Code to "qualified investors" (investisseurs qualifiés) (as such term is defined in Article 2(e) of Prospectus Regulation) acting for their own account, and in accordance with Articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

European Economic Area

In relation to each Member State of the European Economic Area (each, a "Member State") no offer to the public of securities may be made in that Member State other than:

to any legal entity which is a ‘‘qualified investor’’ as defined in the Prospectus Regulation;to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the placement agents for any such offer; orin any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of securities shall require us or any placement agent to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the placement agents and the Company that it is a ‘‘qualified investor’’ as defined in the Prospectus Regulation.
For the purposes of this provision, the expression an "offer to the public" in relation to any securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any ordinary shares.

United Kingdom

This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issuance or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

1 Based on the exchange rate of €1.00 = $1.1576 as published by the European Central Bank on November 12, 2025.

Inventiva - PR - Full Execution of Public Offering - EN - 11 17 2025

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.